Details for Patent: 8,815,301

Which drugs does patent 8,815,301 protect, and when does it expire?

Patent 8,815,301 protects MONOFERRIC and is included in one NDA.

This patent has forty-two patent family members in twenty-five countries.

Summary for Patent: 8,815,301

Title:	Stable iron oligosaccharide compound
Abstract:	The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
Inventor(s):	Andreasen; Hans (Holb.ae butted.k, DK)
Assignee:	Pharmacosmos Holding A/S (Holbaek, DK)
Application Number:	13/138,669
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Process;

Drugs Protected by US Patent 8,815,301

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pharmacosmos As	MONOFERRIC	ferric derisomaltose	SOLUTION;INTRAVENOUS	208171-003	Jan 16, 2020		RX	Yes	Yes			Y	Y		METHOD OF TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE
Pharmacosmos As	MONOFERRIC	ferric derisomaltose	SOLUTION;INTRAVENOUS	208171-001	Jan 16, 2020		DISCN	Yes	No			Y	Y		METHOD OF TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE
Pharmacosmos As	MONOFERRIC	ferric derisomaltose	SOLUTION;INTRAVENOUS	208171-002	Jan 16, 2020		DISCN	Yes	No			Y	Y		METHOD OF TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE

Foreign Priority and PCT Information for Patent: 8,815,301

PCT Information
PCT Filed	March 25, 2009	PCT Application Number:	PCT/DK2009/050069
PCT Publication Date:	September 30, 2010	PCT Publication Number:	WO2010/108493

International Family Members for US Patent 8,815,301

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009342799
Brazil	PI0924653
Canada	2756580